BIO thanked Representative David Schweikert (R-AZ) for introducing H.R. 1952, Spread Pricing Liquidity Act, which is designed to increase liquidity and spur capital formation for small businesses, including emerging biotech companies, that are traded on the public market. In comment, BIO President and CEO Jim Greenwood said that "The Spread Pricing Liquidity Act takes an important step toward granting tick size flexibility to emerging biotech companies."
This story is related to the following:Green & CleanSearch for suppliers of: